The only cancer in the world that can be prevented by a vaccine, yet it remains the second most common cancer in Indian women.
India's first indigenously developed quadrivalent HPV vaccine has been approved by the Drugs Controller General of India (DCGI) and is being incorporated into India's national immunisation schedule.
For the first time in history, affordable, Made-in-India protection against cervical cancer is within reach for every Indian woman.
Of the over 100 known types of cancer, only one can be reliably prevented through vaccination, i.e. cervical cancer. This is not a minor medical footnote - it is one of the most significant breakthroughs in the history of oncology, and yet it remains one of the least utilised in India.
Cervical cancer is caused in nearly 99.7% of cases by persistent infection with the Human Papillomavirus (HPV) - a common virus for which a safe, highly effective vaccine has existed since 2006. In girls vaccinated before their first exposure to HPV, it eliminates up to 90% of cervical cancer cases caused by the most dangerous HPV strains.
Cervical cancer is the only cancer in the world that can be prevented by a vaccine. No other cancer - not breast, not lung, not colon - has this protection available. Every girl who receives the HPV vaccine before exposure significantly reduces her lifetime risk of developing cervical cancer.
Despite this, India continues to carry the second-highest burden of cervical cancer in the world. Approximately 1.25 lakh Indian women are diagnosed with cervical cancer every year, and over 75,000 die from it - a death toll that is almost entirely preventable.
| Key Indicator | Details |
| Annual Diagnoses in India | Approximately 1.25 lakh women are diagnosed with cervical cancer every year. |
| Annual Deaths in India | Around 75,000 women die from cervical cancer annually, despite it being largely preventable. |
| Global Rank | India has the second-highest cervical cancer burden in the world. |
| HPV Causation | About 99.7% of cervical cancer cases are linked to Human Papillomavirus (HPV) infection. |
| Vaccine Effectiveness | The HPV vaccine can prevent up to 90% of cervical cancer cases when administered before HPV exposure. |
| Cervavac (India) | Cervavac, India's first indigenous HPV vaccine, has been approved by the Drug Controller General of India (DCGI) and is being integrated into immunisation efforts. |
| Optimal Age for Vaccination | The recommended age for HPV vaccination is 9–14 years, before sexual debut, to ensure maximum protection. |
| Screenable & Treatable | Cervical cancer is highly preventable and 100% curable when detected at the pre-cancerous stage through regular screening and timely treatment. |
The Human Papillomavirus (HPV) is an extremely common virus - so common that most sexually active individuals will be exposed to at least one strain at some point in their lifetime. There are over 200 strains of HPV; the majority are harmless and clear naturally within two years.
However, approximately 14 strains of HPV are classified as high-risk or oncogenic - meaning they have the potential to cause cancer. Of these, HPV 16 and HPV 18 are responsible for approximately 70% of all cervical cancer cases worldwide.
Read More: Silent Heart Attack: Warning Signs
The Progression from HPV to Cervical Cancer-
| Stage | What Happens | Timeline |
| HPV Infection | High-risk HPV infects the cells of the cervix, usually without causing any noticeable symptoms. | Can occur at any age after sexual debut |
| Persistent Infection | While most HPV infections clear naturally, some persist in the body for an extended period. | Typically 2–5 years after infection |
| Pre-cancerous Changes (CIN) | Persistent HPV infection leads to abnormal cell changes in the cervix, known as Cervical Intraepithelial Neoplasia (CIN), which can be detected through screening tests such as a Pap smear. | Usually 5–10 years after infection |
| Cervical Cancer | If pre-cancerous lesions are not detected and treated, they may gradually develop into invasive cervical cancer. | Generally 10–20 years after infection |
Because cervical cancer takes 10 to 20 years to develop from an initial HPV infection, there is a wide, reliable window during which vaccination, screening, and early intervention can completely prevent or cure the disease. This is what makes cervical cancer uniquely preventable among all cancers.
In a landmark public health decision, the Government of India has officially announced the inclusion of the HPV vaccine in India's Universal Immunisation Programme (UIP) - one of the most significant additions to India's national vaccination schedule in recent years.
H3- Government of India’s Efforts to Prevent Cervical Cancer
HPV Vaccination - India's National Immunisation Programme
The Union Budget 2024-25 announced the nationwide roll-out of HPV vaccination for girls aged 9 to 14 years across India - a decision that has the potential to prevent hundreds of thousands of cervical cancer deaths over the coming decades. The programme is being implemented through the School Health Programme under Ayushman Bharat and is targeted at girls in Classes 6 to 9 in government schools across the country.
Key highlights of India's HPV vaccination initiative:
The World Health Organisation's global strategy to eliminate cervical cancer calls for 90% of girls to be fully vaccinated by age 15, 70% of women screened by ages 35 and 45, and 90% of women with cervical disease to receive treatment. India's national HPV programme is a direct step toward meeting this target.
CERVAVAC - MADE IN INDIA, FOR INDIA | Approved by DCGI
Cervavac is India's first indigenously developed quadrivalent Human Papillomavirus (HPV) vaccine, developed by the Serum Institute of India in Pune, the world's largest vaccine manufacturer. It was approved by the Drugs Controller General of India (DCGI) in 2022 and represents a watershed moment in India's medical self-sufficiency and public health capability.
Cervavac protects against four high-risk HPV strains - HPV 6, 11, 16, and 18. HPV 16 and 18 together cause approximately 70% of all cervical cancers, while HPV 6 and 11 cause approximately 90% of genital warts.
Crucially, Cervavac is available at a fraction of the cost of imported HPV vaccines - making it accessible to the vast majority of Indian families who were previously priced out of HPV protection. It is now being incorporated into India's Universal Immunisation Programme, meaning eligible girls will receive it free of charge through government health facilities and schools.
| Parameter | Details |
| Developer | Serum Institute of India, Pune |
| Type | Quadrivalent HPV Vaccine that protects against HPV types 6, 11, 16, and 18 |
| Approval | Approved by the Drugs Controller General of India (DCGI) |
| Programme | Included in India's Universal Immunisation Programme (UIP) |
| Target Age | Primarily recommended for girls aged 9–14 years |
| Significance | India's first indigenous HPV vaccine is helping to significantly reduce the cost of cervical cancer prevention and improve vaccine accessibility nationwide |
Before Cervavac, the only HPV vaccines available in India were imported - Gardasil and Cervarix - priced between Rs 2,500 and Rs 3,500 per dose. For a three-dose course, the cost exceeded Rs 10,000, placing it beyond the reach of most Indian families. Cervavac's domestic production makes HPV vaccination accessible at a fraction of this cost, potentially reaching the estimated 220 million girls and young women currently unvaccinated in India.
Read More: PCOS in Women: Symptoms, Causes, Fertility Impact & Treatment: A Complete Guide
The HPV vaccine works best when given before a person's first exposure to the virus. This is why early adolescence is the ideal window for vaccination. However, the vaccine still offers meaningful protection for older adolescents and young adults who have not previously been exposed to the specific HPV strains covered by the vaccine.
| Age Group | Recommendation | Dose Schedule |
| Girls aged 9–14 years | Strongly recommended, as this age group receives the highest level of protection and immune response. | 2 doses: At 0 and 6 months |
| Girls and Women aged 15–26 years | Recommended, especially for those who have not been exposed to all HPV strains covered by the vaccine. | 3 doses: At 0, 1–2, and 6 months |
| Women aged 27–45 years | Vaccination may still be beneficial; consultation with a gynaecologist is advised based on individual HPV exposure history. | 3 doses: As recommended by the doctor |
| Boys aged 9–14 years | Recommended in many countries to reduce HPV transmission and protect against HPV-related cancers. | 2–3 doses: According to the prescribed schedule |
The HPV vaccine does not protect against all strains of HPV that can cause cervical cancer. Regular cervical screening — Pap smear and HPV DNA testing — remains essential for all women, vaccinated or not, from the age of 21 or within 3 years of first sexual activity. Vaccination and screening together provide the most comprehensive protection available.
Early-stage cervical cancer is often entirely silent, producing no symptoms whatsoever. This is precisely why regular screening is so critical. However, as the disease progresses, the following warning signs may appear. Any of these symptoms, persisting beyond two weeks, requires prompt gynaecological evaluation.
100%cure rate when cervical cancer is caught at the pre-cancerous stage. Screening saves lives — and the symptoms below are your body's late-stage call for help.
Bleeding between menstrual periods, after sexual intercourse, or after menopause is one of the most common and significant early symptoms of cervical cancer. Even a small amount of post-coital spotting that occurs repeatedly should not be dismissed.
Do not dismiss it as irregular periods, hormonal fluctuations, or vaginal dryness.
Discharge that is watery, pink, brown, or blood-tinged — particularly if it has an unusual or unpleasant odour — can be an early indicator of cervical cancer. Changes in the character of vaginal discharge that persist beyond a few weeks should always be investigated.
Do not dismiss it as a routine infection or yeast problem without medical evaluation.
Persistent pain or pressure in the pelvis — not associated with menstrual cramps — can indicate cervical cancer, particularly in more advanced stages where the tumour presses on surrounding pelvic structures. Pain during sexual intercourse is also a significant warning sign.
Do not dismiss it as muscle pain, UTI, or ovarian cysts without investigation.
The cervix is directly contacted during sexual intercourse, making post-coital bleeding or pain one of the most specific early warning signs of cervical pathology. Any bleeding after sex - however minimal - that occurs more than once is a red flag requiring a Pap smear and gynaecological examination.
Do not dismiss it as roughness during intercourse or vaginal dryness without a check-up.
In more advanced cervical cancer, the tumour can press on nerves or lymph nodes in the pelvis, causing referred pain in the lower back, hips, or legs. Leg swelling may also occur if pelvic lymph nodes are involved.
Do not dismiss it as sciatica or postural back pain without ruling out gynaecological causes.
Read More: Screen Time Is Stealing Your Eyesight
Advanced cervical cancer can invade or press on the bladder, causing painful urination, blood in the urine, or a persistent urge to urinate. These symptoms are often mistaken for recurrent urinary tract infections and treated with antibiotics without investigating the underlying cause.
Do not dismiss it as another UTI without a pelvic examination if it recurs frequently.
Cervical cancer can cause systemic symptoms including profound unexplained fatigue, loss of appetite, and unintentional weight loss — particularly in more advanced disease. When these symptoms occur alongside any gynaecological symptoms, they represent a significant clinical red flag.
Do not dismiss it as stress, overwork, or dietary changes without medical evaluation.
A sudden change in the pattern of menstrual periods — heavier bleeding, significantly longer duration, or periods that are more painful than usual — can indicate cervical pathology. Cervical cancer should always be ruled out with a Pap smear and pelvic examination when these symptoms are new or worsening.
Do not dismiss it as a hormonal imbalance or PCOS without a cervical examination.
- Screening - Smear and HPV Test Guide
Cervical cancer screening can detect pre-cancerous changes in the cervix years before they develop into cancer — giving doctors and patients the opportunity to intervene when cure rates are at their highest. In India, low screening rates remain one of the primary drivers of late-stage diagnosis and high cervical cancer mortality.
The Two Primary Screening Tests:
A sample of cells from the cervix is collected and examined under a microscope for abnormal changes. Quick, affordable, and widely available. Recommended every 3 years for women aged 21–65 or as advised by your gynaecologist.
Tests directly for the presence of high-risk HPV strains in cervical cells. More sensitive than Pap smear alone. Recommended every 5 years from age 30 onwards, often in combination with Pap smear (co-testing).
H3- 3. Colposcopy
If Pap smear or HPV test results are abnormal, a colposcopy is performed — a magnified examination of the cervix to identify the precise location and extent of abnormal cells for biopsy and diagnosis.
H4- 4. Visual Inspection with Acetic Acid (VIA)
A low-cost, no-laboratory screening method widely used in rural India — acetic acid is applied to the cervix, and abnormal areas turn white. Effective for screening in resource-limited settings.
| Age Group | Recommended Screening | Frequency |
| Below 21 years | No routine screening needed (even if sexually active) | — |
| 21 to 29 years | Pap smear alone | Every 3 years |
| 30 to 65 years | Pap smear + HPV co-test (preferred) | Every 5 years |
| Above 65 years | Can stop if 3 consecutive normal Pap results | As advised by the doctor |
| Post-hysterectomy | Not required if the uterus and cervix are both removed | — |
When detected early — at the pre-cancerous or early invasive stage — cervical cancer is among the most treatable cancers. Treatment depends on the stage at diagnosis, the patient's age, and fertility considerations.
| Stage | Description | Treatment Options | Approximate Survival Rate |
| Pre-cancer (CIN 1–3) | Abnormal cells are present in the cervix but have not yet developed into cancer. | LEEP, cryotherapy, cone biopsy | Nearly 100% |
| Stage I | Cancer is confined to the cervix. | Surgery, radiation therapy | ~80–93% |
| Stage II | Cancer has spread beyond the cervix but not to distant organs. | Chemoradiation, radical surgery | ~58–63% |
| Stage III | Cancer has spread to the pelvic wall and/or lower vagina. | Concurrent chemoradiation | ~32–35% |
| Stage IV | Cancer has spread to distant organs such as the lungs, liver, or bones. | Palliative care, immunotherapy, targeted treatments | ~15–16% |
The 5-year survival rate for cervical cancer detected at Stage I is over 80%. Detected at Stage IV, that figure drops to 15%. The difference between these outcomes is almost entirely a matter of when the cancer is found, which is entirely within a woman's control through regular screening.
Cervical cancer holds a distinction that no other cancer in the world can claim: it is almost entirely preventable. We have the vaccine. We have the screening tests. We have the medical knowledge. And now, for the first time, we have an affordable, Made-in-India vaccine — Cervavac — being delivered to girls across the country through a government programme that represents one of the most significant public health commitments India has made in a generation.
The only thing standing between a girl and lifetime protection from cervical cancer is a vaccine appointment. The only thing standing between a woman and a curable early-stage diagnosis is a Pap smear.
If you have a daughter between 9 and 14 years old — book her HPV vaccination today. If you are a woman between 21 and 65 who has not had a Pap smear in the last three years — book your screening today.
Cervical cancer kills over 75,000 Indian women every year. Not one of those deaths needs to happen. Start with one appointment — today.
Read More: Silent Warning Signs of Kidney Disease Most People Ignore Until It's Too Late
Q1. Is cervical cancer really the only cancer preventable by a vaccine?
Ans. Yes - cervical cancer is currently the only cancer in the world for which a preventive vaccine exists and is widely recommended. The HPV vaccine works by preventing infection with the specific virus strains responsible for the vast majority of cervical cancers. No vaccine currently exists for breast cancer, lung cancer, colorectal cancer, or any other major cancer type. This makes the HPV vaccine a truly extraordinary and historically unprecedented public health tool.
Q2. What is Cervavac and how is it different from Gardasil or Cervarix?
Ans. Cervavac is India's first indigenously developed quadrivalent HPV vaccine, produced by the Serum Institute of India. Like Gardasil, it protects against HPV strains 6, 11, 16, and 18. The critical difference is cost and accessibility — Cervavac is produced domestically at a significantly lower cost than imported vaccines. It has been approved by the DCGI and is being incorporated into India's Universal Immunisation Programme, meaning eligible girls will receive it free of charge through government channels.
Q3. If my daughter has been vaccinated, does she still need Pap smears?
Ans. Yes - absolutely. The HPV vaccine protects against the most common high-risk HPV strains but does not cover all strains that can cause cervical cancer. Additionally, a small number of cervical cancers are not HPV-related. Regular Pap smear and HPV testing remain essential for all women from age 21 onwards, regardless of vaccination status. Think of vaccination and screening as two complementary layers of protection - neither alone is sufficient.
Q4. Can a woman who is already sexually active get the HPV vaccine?
Ans. Yes - women up to age 45 can receive the HPV vaccine and may still benefit, particularly if they have not previously been exposed to all four HPV strains covered by the vaccine. However, the vaccine's protection is greatest when given before any HPV exposure - which is why vaccination in early adolescence is strongly preferred. Women above 26 should consult their gynaecologist to discuss whether vaccination is appropriate for their individual situation.
Q5. How painful is a Pap smear? Many women in India avoid it due to fear or embarrassment.
Ans. A Pap smear is a quick, minimally uncomfortable procedure that takes approximately 5 to 10 minutes in total. Most women feel only mild pressure or brief cramping during cell collection. The test is performed privately by a trained female gynaecologist or nurse. The discomfort of a Pap smear is temporary and minor — the consequences of an undetected cervical cancer are lifelong and potentially fatal. TMU Hospital's gynaecology team creates a respectful, private, and compassionate environment for all screening appointments.
Q6. Does the Government of India provide HPV vaccination for free?
Ans. Yes - the Government of India has announced the inclusion of HPV vaccination for girls aged 9 to 14 years in the Universal Immunisation Programme, with the vaccine being delivered free of charge through government schools and health centres under the Ayushman Bharat School Health Programme. The vaccine being used in the government programme is Cervavac - India's own indigenously developed HPV vaccine. Girls outside the government programme's target age or those seeking vaccination at private facilities can access HPV vaccination at TMU Hospital through consultation with our gynaecology department.
PCOS in Women: Symptoms, Causes, Fertili...
© TMU Hospital is Proudly Owned by TMU
